Please assess the completion status of the following clinical trial:

Trial Title: Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-myeloid malignancies~* Anemia (hgb less than or equal to 11.0 g/dL) related to cancer and chemotherapy~* Plan to receive cyclic chemotherapy for an additional 8 weeks~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1~* Adequate renal and liver function~* Ability to participate in the MHST based on clinical judgement of investigator~* At least 18 years of age~Exclusion Criteria:~* Iron deficiency~* Received recombinant human erythropoietin (rHuEPO) therapy within 4 weeks prior to enrollment~* Unstable cardiac disease~* Current active condition creating clinical danger for the subject to participate in the MHST~* known positive test for HIV infection~* Previous hematologic disorder associated with anemia~* Currently receiving beta-blockers~* Use of drugs or devices not approved by the FDA for any indication~* Pregnant or breast feeding~* Known hypersensitivity to any recombinant mammalian-derived product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- darbepoetin alfa (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).